Alphamab Oncology, which was spun out of Suzhou Alphamab last year, was approved to IPO in Hong Kong under the Exchange’s pre-revenue rules. The bi-specifics company has eight oncology molecules in development, four of them in clinical trials, and will use the IPO proceeds to support clinical development of its portfolio. Alphamab expects KNO46, potentially a first-in-class bispecific antibody against CTLA-4 and PD-1, to be fast-tracked towards China approval for nasopharyngeal carcinoma in 2022. It is currently in a Phase Ib/II trial.
Source: China Biotoday
